Patients improve after heart cell therapy
Four of six critically ill COVID-19 (coronavirus) patients significantly improved after receiving an experimental therapeutic designed to reduce inflammation, a major cause of death from this disease, according to a case series published by Cedars-Sinai and Capricor Therapeutics. The four patients got well enough to be discharged from the hospital. The therapeutic, known as CAP-1002, contains cardiosphere-derived cells (CDCs) that […]
Continue reading »